Institutional investors purchased a net $721.6 thousand shares of REGN during the quarter ended December 2014. This may signal that the smart money is gaining interest in this company as the 72.76% of the shares outstanding that institutional investors hold is among the lowest in the Biotechnology industry.
Mutual fund holders
Largest Quarterly Institutional Transactions
Latest Institutional Activity
SV LIFE SCIENCES MANAGERS LLP Bought 9.2 Thousand shares of Regeneron Pharmaceuticals
CREDIT SUISSE AG Bought 5.1 Thousand shares of Regeneron Pharmaceuticals